Physician profile
Jonathan Lam
NPI 1962997619
$4,338.25
in general payments reported to CMS, 2019-2025
21 companies · $1,786 in 2025
The $1,786 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2021: $1,442 · 2022: $208 · 2023: $373 · 2024: $429 · 2025: $1,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,588.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,419.06 | 2021 | |
| New World Medical,INC. | $407.36 | 2023-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Johnson & Johnson Surgical Vision, INC. | $400.24 | 2023-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Abbvie INC. | $365.34 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $311.03 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $294.75 | 2023-2025 | Eysuvis, Clareon Panoptix Pro, Clareon |
| Harrow Eye, LLC | $167.26 | 2024-2025 | Vevye, Iheezo |
| Bausch & Lomb Americas INC. | $140.85 | 2025 | Vyzulta, Scoutpro Osmolarity System |
| Eyevance Pharmaceuticals LLC | $123.80 | 2022 | |
| Rayner Intraocular Lenses Limited | $122.55 | 2023 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Allergan, INC. | $99.99 | 2019 | |
| Ani Pharmaceuticals, INC. | $95.29 | 2024-2025 | Purified Cortrophin Gel |
| Glaukos Corporation | $91.18 | 2025 | Idosetr |
| Rxsight INC | $84.10 | 2022 | |
| Ocular Therapeutix, INC. | $64.00 | 2024-2025 | Dextenza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $39.11 | 2024 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $27.78 | 2025 | Acthar |
| Astellas Pharma US INC | $25.07 | 2023 | |
| Horizon Therapeutics Plc | $23.10 | 2021 | |
| Genentech USA, INC. | $19.72 | 2025 | Vabysmo |
| Sight Sciences, INC. | $16.67 | 2025 | Sion Surgical Instrument, Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.